NY-ESO-1

NY-ESO-1 is a human tumor antigen of the cancer/testis family.[1] It is highly expressed in many poor-prognosis melanomas.[2]

It is being studied as possible target for a cancer vaccine or immunotherapy.

It is a target for some experimental engineered T-cell therapies for myeloma.[3]

See also

References

  1. ↑ Gnjatic, S; et al. (2006). "NY-ESO-1: review of an immunogenic tumor antigen". Advances in Cancer Research. 95: 1–30. doi:10.1016/S0065-230X(06)95001-5. PMID 16860654.
  2. ↑ van Rhee, F (15 May 2005). "NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses" (PDF). Blood. 105 (10): 3939–3944. doi:10.1182/blood-2004-09-3707. PMC 1895070. PMID 15671442.
  3. ↑ Rapoport, AP; et al. (20 July 2015). "NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma". Nature Medicine. 21 (8): 914–921. doi:10.1038/nm.3910. PMC 4529359. PMID 26193344.

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8.

PMID 9050879

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.